The new EU compass could support small companies to grow their market share across Europe, assisted by fewer regulatory ...

as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly. Mazdutide – a once-weekly injectable Innovent licensed from Lilly – was submitted to China's ...

Other GLP-1-targeting drugs for obesity and diabetes are also being explored for their potential in MASH – including Novo Nordisk’s Ozempic/Wegovy (semaglutide) and Eli Lilly’s Mounjaro ...

SY-009 is a novel SGLT1 inhibitor, that is not listed at home or abroad. With the permission of Eli Lilly Company, Suzhou Yabao Pharmaceutical Research and Development Co., Ltd., initiated the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Copyright 2025 The Associated Press. All Rights Reserved. A sign for Eli Lilly & Co. appears outside their corporate ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...